Loading
Lisata Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by MYERS STEVEN S, was filed 10 Dec 2021.
Lisata Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Lisata Therapeutics, Inc. as filed with SEC (Form 4), a company from the Health Care sector. In the past year (23 October 2025 to 23 October 2026), 23 filings came from 9 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
With 23 filings in twelve months, the company is quieter than the median of 24 filings across the 3,167 companies we follow on the same exchange. The full history, which starts in 2016, counts 2 purchases against 14 sales. The 10-K for the year ended 31 December 2025 shows 170,000 USD of revenue and -16.6 m USD of net income.
There has been no open-market purchase by an insider of Lisata Therapeutics, Inc. for at least a year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
254
Thresholds
n/a
Buy Volume
€111,426
2 ops. · all time
Sell Volume
€202,101
14 ops. · all time
Since the insiders bought
- -77.7%Entry US$13.50 · Close at T+365 US$3.01
- -35.9%Entry US$29.25 · Close at T+365 US$18.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.00
Analyst consensus
Income statement
RevenueUS$170k
EBITDA-US$18.1M-10625% margin
Net income-US$16.6M-9756.5% margin
Valuation
PER (forward)-0.9x
P/Book1.1x
Beta0.95
Balance sheet & cash
Market capUS$10.8M
Free Cash Flow-US$16M
Profitability & ownership
ROE-101.7%
ROA-56.7%
% insiders22.3%
% institutions11.2%
Last declaration on 13 January 2026
Declarations254 total
1,137 shares@ US$1.975.3% of flowCommon StockSEC:0002020260-26-000003:3
10,503 shares@ US$1.971.4% of flowCommon StockSEC:0001334549-26-000003:1
10,515 shares@ US$1.971.4% of flowCommon StockSEC:0001334549-26-000003:2
12,224 shares@ US$1.971.6% of flowCommon StockSEC:0001334549-26-000003:3
7,854 shares@ US$1.971.0% of flowCommon StockSEC:0001334549-26-000003:4
1,401 shares@ US$1.9740.0% of flowCommon StockSEC:0002055011-26-000003:1
840 shares@ US$1.9724.0% of flowCommon StockSEC:0002055011-26-000003:2
747 shares@ US$1.9721.3% of flowCommon StockSEC:0002055011-26-000003:3
513 shares@ US$1.9714.7% of flowCommon StockSEC:0002055011-26-000003:4
2,131 shares@ US$1.979.9% of flowCommon StockSEC:0002020260-26-000003:1
781 shares@ US$1.973.6% of flowCommon StockSEC:0002020260-26-000003:4
15,000 shares0Common StockSEC:0002055011-26-000003:0
2,982 shares@ US$1.978.4% of flowCommon StockSEC:0001879231-26-000003:1
3,221 shares@ US$1.979.1% of flowCommon StockSEC:0001879231-26-000003:3
2,147 shares@ US$1.976.1% of flowCommon StockSEC:0001879231-26-000003:4
30,456 shares0Common StockSEC:0001309653-26-000004:0
30,456 shares0Common StockSEC:0001373585-26-000003:0
25,000 shares0Common StockSEC:0001879231-26-000003:0
15,000 shares0Common StockSEC:0002020260-26-000003:0
30,456 shares0Common StockSEC:0001741455-26-000003:0
81,000 shares0Common StockSEC:0001334549-26-000003:0
30,456 shares0Common StockSEC:0001283301-26-000003:0
30,456 shares0Common StockSEC:0001192621-26-000004:0
7,017 shares@ US$3.802.0% of flowCommon StockSEC:0001334549-25-000002:3
781 shares@ US$3.807.9% of flowCommon StockSEC:0002020260-25-000002:3
25 of 254 declarations
About Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc. is a company focused on developing innovative therapies for the treatment of diseases. It is listed on the XNAS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
